NCT05178654View on ClinicalTrials.gov

Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]PF-07321332 in Healthy Male Participants.

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 22, 2022

Primary Completion Date

April 1, 2022

Study Completion Date

April 1, 2022

Conditions
Healthy Participants
Interventions
DRUG

[14C]PF-07321332

Single oral dose of 300 mg \[14C\]PF-07321332 containing approximately 100 µCi \[14C\]PF-07321332 coadministered with 100 mg ritonavir.

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05178654 - Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]PF-07321332 in Healthy Male Participants. | Biotech Hunter | Biotech Hunter